Premium
Serum concentration of intercellular adhesion molecule–1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis
Author(s) -
Shimizu Yukihiro,
Minemura Masami,
Tsukishiro Takashi,
Kashii Yoshirou,
Miyamoto Megumi,
Nishimori Hiroshi,
Higuchi Kiyohiro,
Watanabe Akiharu
Publication year - 1995
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840220223
Subject(s) - hepatocellular carcinoma , intercellular adhesion molecule 1 , medicine , intracellular , adhesion , disease , cell adhesion molecule , carcinoma , pathology , cancer research , oncology , chemistry , immunology , biochemistry , organic chemistry
Serum levels of soluble forms of intercellular adhesion molecule–1 (sICAM‐1) and lymphocyte function‐associated antigen‐3 (sLFA‐3) in 122 patients with chronic liver disease including hepatocellular carcinoma (HCC) were measured by enzyme‐linked immunosorbent assays. Serum levels of sICAM‐1 in patients with HCC were significantly higher than those of chronic hepatitis (CH) and cirrhosis. On the other hand, serum levels of sLFA‐3 in patients with HCC were almost the same as those of cirrhosis. Western blot analyses showed that molecular sizes of sICAM‐1 and sLFA‐3 detected in the sera were 90 kd and 50 kd, respectively, indicating that both molecules include whole extracellular domains. In patients with HCC, circulating sICAM‐1 levels were significantly ( P < .001) correlated with tumor volume ( r = .50), total bilirubin ( r = .38), serum aspartate aminotransferase levels ( r = .51), and γ‐globulin ( r = .63). Furthermore, serum sICAM‐1 levels were significantly elevated in patients with multiple HCC (tumor number >3) or HCC with tumor embolus in the first branch or trunk of portal vein. Survival periods were analyzed in relation to serum sICAM‐1 levels in patients with HCC who had been treated by transcatheter arterial chemoembolization. The HCC patients with <1,000 ng/mL of serum ICAM‐1 showed significantly ( P = .0005) longer survival than those with higher levels of the molecule. The same results were obtained when only patients with moderately differentiated HCC were analyzed ( P = .02). Analyses by Cox's proportional hazard model showed that sICAM‐1 is a significant ( P = .032) prognostic factor for patients with HCC. These data show that circulating sICAM‐1 in the sera of patients with HCC is a marker for tumor progression and prognosis of the patients. (Hepatology 1995; 22:525–531.)